Literature DB >> 6505951

Ophthalmic drug delivery systems.

J W Shell.   

Abstract

In recent years, increased attention has been given to the development of new systems for the delivery of ophthalmic medication. These systems are of interest for several reasons: they generally require less frequent administration than eyedrops; some of them provide therapy with fewer drug side effects than eyedrops; and they can offer practical advantages in situations where repeated, self-medication by patients is not feasible. Further, by providing continuous delivery, they allow the use of some newly emerging drugs that have very short biological half-lives. Some ocular delivery systems extend the duration of drug action by enhancement of corneal absorption; these include soluble gels and emulsions, hydrophilic ocular inserts, ion-pair associations, pro-drugs, and liposomes. Other delivery systems provide for a controlled release of drugs, thus avoiding the pulse-entry with which side-effects are associated. These systems can be based on any of several different mechanisms, and include both erodible and nonerodible matrices. The various new systems that have been developed, or are known to be under development, are described in this review, along with their mechanisms and limitations, and with the therapeutic rationale for their use.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6505951     DOI: 10.1016/0039-6257(84)90168-1

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  12 in total

1.  Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea.

Authors:  Leslie N Johnson; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

2.  Mini drug pump for ophthalmic use.

Authors:  Saloomeh Saati; Ronalee Lo; Po-Ying Li; Ellis Meng; Rohit Varma; Mark S Humayun
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

Review 3.  Topical medication instillation techniques for glaucoma.

Authors:  Li Xu; Xuemei Wang; Meijing Wu
Journal:  Cochrane Database Syst Rev       Date:  2017-02-20

4.  The kinetics of timolol in the rabbit lens: implications for ocular drug delivery.

Authors:  I Ahmed; M L Francoeur; A G Thombre; T F Patton
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

5.  Controlled delivery of pilocarpine. 1. In vitro characterization of Gelfoam matrices.

Authors:  S R Nadkarni; S H Yalkowsky
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

6.  The contralateral reduction of intraocular pressure by timolol.

Authors:  C N Dunham; R F Spaide; G Dunham
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

7.  Mini drug pump for ophthalmic use.

Authors:  Saloomeh Saati; Ronalee Lo; Po-Ying Li; Ellis Meng; Rohit Varma; Mark S Humayun
Journal:  Curr Eye Res       Date:  2010-03       Impact factor: 2.424

8.  Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation.

Authors:  Srinivas Rao Chennamaneni; Christina Mamalis; Bonnie Archer; Zack Oakey; Balamurali K Ambati
Journal:  J Control Release       Date:  2013-01-13       Impact factor: 9.776

9.  Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study.

Authors:  F P Gunning; E L Greve; A M Bron; J M Bosc; J G Royer; J L George; P Lesure; D Sirbat
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-07       Impact factor: 3.117

10.  A drug-eluting contact lens.

Authors:  Joseph B Ciolino; Todd R Hoare; Naomi G Iwata; Irmgard Behlau; Claes H Dohlman; Robert Langer; Daniel S Kohane
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-10       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.